Using a new approach to treat liver malignancies, researchers at Heinrich-Heine-University in Dusseldorf, Germany, have demonstrated that adult bone marrow stem cells accelerate the regeneration of healthy liver tissue in humans.
Using a new approach to treat liver malignancies, researchers at Heinrich-Heine-University in Dusseldorf, Germany, have demonstrated that adult bone marrow stem cells accelerate the regeneration of healthy liver tissue in humans.
Portal vein embolization (PVE) is currently used to stimulate liver tissue growth for these patients. It redirects portal blood flow to the healthy portion of the liver to induce hypertrophy. In a study published in the April issue of Radiology, CT helped compare PVE with a combination of PVE and injected bone marrow stem cells in the liver.
Thirteen patients with central liver malignancies underwent PVE of liver segments I and IV to VIII to stimulate hepatic regeneration before hepatectomy. Researchers determined that PVE would be inadequate for six patients with future liver remnant volumes below 25% of presurgical liver volume and/or limited quality liver tissue. These patients were administered PVE and CD133+ bone marrow stem cells. The other seven patients, with future liver remnant volumes that were greater than 25%, received only PVE.
CT was used to measure liver and tumor volumes before and up to five weeks after PVE to determine liver growth. No labeling of the applied hematopoietic stem cells was performed.
Imaging revealed that the liver growth rate and gain in liver volume doubled in patients who received the combination of PVE and stem cell injection compared with those who underwent only PVE. The daily hepatic volume growth rate in the stem cell group averaged 9.5 mL per day compared with 4.1 mL per day in the PVE-only group.
The relative gain in future liver remnant volume (equivalent to the relative left lateral liver volume growth related to the preinterventional total liver volume) averaged 77.3% in the stem cell group and 39.1% in the group treated with PVE alone. As a result, patients who received the combined treatment could undergo surgery an average of 18 days sooner than patients who received PVE alone.
CD133+ cell implantation and PVE appear to be a potent combination, said coauthor Dr. Günter Fürst, a professor of radiology at Heinrich-Heine.
"Patients can minimize the possibility of tumor advance beyond resectability and shorten the waiting time to life-saving surgery," he said.
A randomized multicenter trial is planned. If the results are again positive, Fürst and collaborator Dr. Jan Schulte am Esch will test if stem cell-stimulated tissue regeneration can treat fulminant hepatic failure without preexisting liver disease and acute-on-chronic liver failure in cirrhotic patients.
For more information from the Diagnostic Imaging archives:
Report from ECR: Contrast-enhanced ultrasound shines in detecting liver metastases
Portal vein embolization provides hope in cancer
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.